Edwards Lifesciences (EW) insider trading
Insider activity, historical context and SEC filings · data through Nov 20, 2026
No open-market insider buying in the last 12 months. Selling alone is common (taxes, diversification, pre-planned 10b5-1 sales) and isn't treated as a signal here.
Label: Heavy selling · based on open-market trades (codes P and S), last 12 months. Not a rating or advice.- Next earnings expected around Feb 15, 2027 (estimate from past release dates). Insiders usually trade in the weeks after results; past reactions ↓
Sale Daniel J. Lippis, Cvp, Tavr sold 619 shares at $104.25 ($65K).
- Trade date
- Nov 10, 2026
- Disclosed to the SEC
- Nov 10, 2026
- Type
- Pre-planned sale, 10b5-1 (code S)
Read the original SEC filing ↗All EW insider trades ↓
Insiders have two business days to report a trade to the SEC, so filings (and our alerts) always come after the trade, never in real time.
EW insider transactions (Form 4)
Open-market purchases and sales. 107 grants, option exercises and tax withholdings are not shown.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Nov 10SEC | Daniel J. LippisCvp, Tavr | Sell Plan | 61940,034 held (−2%) | $104.25 | $65K | -0.5% | — |
| Nov 9SEC | Donald E. Bobo Jr.Cvp,Strategy/Corp Development | Sell Plan | 48,90022,798 held (−68%) | $103.05 | $5.0M | +0.6% | — |
| Nov 9SEC | Bernard J. ZovighianCEO | Sell Plan | 13,91698,845 held (−12%) | $102.78 | $1.4M | +0.9% | — |
| Nov 9SEC | Bernard J. ZovighianCEO | Sell Plan | 9,184112,761 held (−8%) | $103.39 | $949K | +0.3% | — |
| Oct 8SEC | Daniel J. LippisCvp, Tavr | Sell Plan | 61940,034 held (−2%) | $85.65 | $53K | +21.1% | — |
| Sep 11SEC | Daniel J. LippisCvp, Tavr | Sell Plan | 61940,034 held (−2%) | $87.51 | $54K | +18.5% | — |
| Aug 31SEC | Andrew M. DahlSvp, Corporate Controller | Sell | 54414,868 held (−4%) | $91.06 | $50K | +13.9% | — |
| Aug 28SEC | Annette BrulsCvp, Emeacla | Sell | 2,64417,984 held (−13%) | $89.98 | $238K | +15.3% | — |
| Aug 26SEC | Daveen ChopraCvp, Tmtt, Surgical & Ihfm | Sell | 30,64644,324 held (−41%) | $90.99 | $2.8M | +14.0% | — |
| Aug 26SEC | Wayne MarkowitzCvp, Japac | Sell | 1,24020,294 held (−6%) | $91.47 | $113K | +13.4% | — |
| Aug 26SEC | Daveen ChopraCvp, Tmtt, Surgical & Ihfm | Sell | 1,15474,970 held (−2%) | $91.76 | $106K | +13.0% | — |
| Aug 11SEC | Daniel J. LippisCvp, Tavr | Sell Plan | 61940,034 held (−2%) | $92.03 | $57K | +12.7% | — |
| Jul 30SEC | Wayne MarkowitzCvp, Japac | Sell | 14621,534 held (−1%) | $86.03 | $13K | +20.6% | — |
| Jul 28SEC | Wayne MarkowitzCvp, Japac | Sell | 9,62821,680 held (−31%) | $85.06 | $819K | +21.9% | — |
| Jul 27SEC | Bernard J. ZovighianCEO | Sell | 2,9218,916 held (−25%) | $83.93 | $245K | +23.6% | — |
| Jul 10SEC | Daniel J. LippisCvp, Tavr | Sell Plan | 61940,034 held (−2%) | $91.70 | $57K | +13.1% | — |
| Jun 30SEC | Daniel J. LippisCvp, Tavr | Sell Plan | 61940,411 held (−2%) | $91.40 | $57K | +13.5% | — |
| Jun 17SEC | Bernard J. ZovighianCEO | Sell Plan | 52311,517 held (−4%) | $87.92 | $46K | +18.0% | — |
| May 29SEC | Andrew M. DahlSvp, Corporate Controller | Sell | 56815,334 held (−4%) | $86.08 | $49K | +20.5% | — |
| May 27SEC | Donald E. Bobo Jr.Cvp,Strategy/Corp Development | Sell | 23,14598,611 held (−19%) | $86.42 | $2.0M | +20.0% | — |
| May 22SEC | Daveen ChopraCvp, Tmtt & Surgical | Sell | 1,50044,324 held (−3%) | $84.60 | $127K | +22.6% | — |
| May 18SEC | Donald E. Bobo Jr.Cvp,Strategy/Corp Development | Sell | 9,96822,798 held (−30%) | $82.07 | $818K | +26.4% | — |
| May 18SEC | Donald E. Bobo Jr.Cvp,Strategy/Corp Development | Sell | 8,00030,970 held (−21%) | $81.82 | $655K | +26.8% | — |
| May 18SEC | Daniel J. LippisCvp, Tavr | Sell Plan | 62040,411 held (−2%) | $81.14 | $50K | +27.8% | — |
| May 12SEC | Bernard J. ZovighianCEO | Sell Plan | 35,50612,040 held (−75%) | $77.92 | $2.8M | +33.1% | — |
| May 12SEC | Bernard J. ZovighianCEO | Sell Plan | 84547,546 held (−2%) | $78.40 | $66K | +32.3% | — |
| May 11SEC | Wayne MarkowitzCvp, Japac | Sell | 59321,680 held (−3%) | $79.73 | $47K | +30.1% | — |
| May 4SEC | Daniel J. LippisCvp, Tavr | Sell Plan | 1,01933,682 held (−3%) | $83.98 | $86K | +23.5% | — |
| May 4SEC | Daniel J. LippisCvp, Tavr | Sell Plan | 1,00033,934 held (−3%) | $82.99 | $83K | +25.0% | — |
| May 4SEC | Daniel J. LippisCvp, Tavr | Sell Plan | 1934,934 held (−0%) | $83.99 | $2K | +23.5% | — |
| Apr 9SEC | Scott B. UllemCFO | Sell Plan | 8,32439,699 held (−17%) | $79.79 | $664K | +30.0% | — |
| Apr 9SEC | Scott B. UllemCFO | Sell Plan | 4,67648,023 held (−9%) | $80.50 | $376K | +28.9% | — |
| Apr 6SEC | Daniel J. LippisCvp, Tavr | Sell Plan | 1,01933,934 held (−3%) | $80.98 | $83K | +28.1% | — |
| Apr 2SEC | Donald E. Bobo Jr.Cvp,Strategy/Corp Development | Sell Plan | 18,00421,266 held (−46%) | $80.05 | $1.4M | +29.6% | — |
| Apr 2SEC | Donald E. Bobo Jr.Cvp,Strategy/Corp Development | Sell Plan | 4,67639,270 held (−11%) | $80.59 | $377K | +28.7% | — |
| Mar 11SEC | Scott B. UllemCFO | Sell Plan | 7,90139,699 held (−17%) | $85.21 | $673K | +21.7% | — |
| Mar 11SEC | Scott B. UllemCFO | Sell Plan | 5,09947,600 held (−10%) | $84.46 | $431K | +22.8% | — |
| Mar 11SEC | Daniel J. LippisCvp, Tavr | Sell Plan | 1,01933,934 held (−3%) | $85.38 | $87K | +21.5% | — |
| Mar 2SEC | Donald E. Bobo Jr.Cvp,Strategy/Corp Development | Sell Plan | 11,34021,266 held (−35%) | $85.93 | $974K | +20.7% | — |
| Feb 26SEC | Donald E. Bobo Jr.Cvp,Strategy/Corp Development | Sell | 24,00021,266 held (−53%) | $83.84 | $2.0M | +23.7% | — |
| Feb 13SEC | Bernard J. ZovighianCEO | Sell | 19,89883,896 held (−19%) | $76.61 | $1.5M | +35.4% | — |
| Feb 13SEC | Bernard J. ZovighianCEO | Sell | 2,532103,794 held (−2%) | $77.13 | $195K | +34.5% | — |
| Jan 9SEC | Daniel J. LippisCvp, Tavr | Sell Plan | 1,01922,002 held (−4%) | $85.70 | $87K | +21.0% | — |
| Jan 6SEC | Donald E. Bobo Jr.Cvp,Strategy/Corp Development | Sell Plan | 8,70831,870 held (−21%) | $85.98 | $749K | +20.6% | — |
| Jan 6SEC | Donald E. Bobo Jr.Cvp,Strategy/Corp Development | Sell Plan | 2,63240,578 held (−6%) | $84.62 | $223K | +22.6% | — |
| Dec 12SEC | Donald E. Bobo Jr.Cvp,Strategy/Corp Development | Sell | 5,90038,970 held (−13%) | $83.74 | $494K | +23.9% | — |
| Dec 12SEC | Donald E. Bobo Jr.Cvp,Strategy/Corp Development | Sell | 5,48644,870 held (−11%) | $83.79 | $460K | +23.8% | — |
| Dec 12SEC | Heisz Leslie StoneDirector | Sell | 2,61530,948 held (−8%) | $83.41 | $218K | +24.3% | — |
| Dec 12SEC | Daniel J. LippisCvp, Japac | Sell Plan | 1,01922,002 held (−4%) | $84.03 | $86K | +23.4% | — |
| Dec 11SEC | Daveen ChopraCvp, Tmtt & Surgical | Sell | 2,00032,201 held (−6%) | $84.38 | $169K | +22.9% | — |
| Dec 10SEC | Bernard J. ZovighianCEO | Sell Plan | 21,48784,839 held (−20%) | $85.21 | $1.8M | +21.7% | — |
| Dec 10SEC | Donald E. Bobo Jr.Cvp,Strategy/Corp Development | Sell Plan | 11,34050,356 held (−18%) | $83.83 | $951K | +23.7% | — |
| Dec 10SEC | Bernard J. ZovighianCEO | Sell Plan | 3,8638,597 held (−31%) | $83.45 | $322K | +24.3% | — |
| Dec 9SEC | Scott B. UllemCFO | Sell Plan | 7,70039,898 held (−16%) | $84.47 | $650K | +22.8% | — |
| Dec 8SEC | Wayne MarkowitzCvp, Japac | Sell | 58317,563 held (−3%) | $86.01 | $50K | +20.6% | — |
| Nov 10SEC | Scott B. UllemCFO | Sell Plan | 10,02639,898 held (−20%) | $83.02 | $832K | +24.9% | — |
| Nov 10SEC | Scott B. UllemCFO | Sell Plan | 2,97449,924 held (−6%) | $83.30 | $248K | +24.5% | — |
| Nov 10SEC | Daniel J. LippisCvp, Japac | Sell Plan | 1,02022,002 held (−4%) | $82.55 | $84K | +25.7% | — |
Similar past setups: not applicable. EW has had no open-market insider purchases in the last 12 months, so there's no buying setup to compare with history. When insiders buy, this section shows how 6,290 similar past buys did over 90 days. How we calculate this →
Play with EW in the Research Lab
EW has no open-market insider buys in the last 12 months. Try the tools with any setup.
Quick backtest: did buys like this beat the market?
Tap a setting to see how 6,290 past insider buys did.
Share price and insider trades
Edwards Lifesciences insider trading at a glance (Nov 20, 2026): in the past 12 months, 0 insiders bought $0 and 9 sold $34.1M of EW stock on the open market; P/E 55.8 vs. a sector median of 25.0.
By InsiderPrint Research Desk · Updated · Sources: SEC EDGAR Form 4 filings, FINRA short-sale volume · How we calculate this
EW insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | $7.5M | 5 |
| Q3 2026 | — | 0 | $4.5M | 11 |
| Q2 2026 | — | 0 | $9.8M | 19 |
| Q1 2026 | — | 0 | $7.0M | 10 |
| Q4 2025 | — | 0 | $6.4M | 13 |
Valuation, profit and volume
Source: SEC filings, as of Nov 16, 2026. Volume and paper profit use daily closing prices.
Summary
Over the past 12 months, 0 Edwards Lifesciences insiders reported open-market purchases totaling $0, while 9 insiders reported sales totaling $34.1M. Among insiders with enough purchase history to measure, Paul A. Laviolette (Director) has the highest Insider Score at 100. 36 of 58 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
EW earnings: how the stock reacted
Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.
| Release | 15 days before | Insiders, 30 days before | Reaction (2 days) | Next 30 days |
|---|---|---|---|---|
| Nov 4, 2026 | +9.1% | Sold $53K | +5.9%S&P -2.8% | pending |
| Jul 23, 2026 | -11.0% | Sold $113K | -2.1%S&P -1.1% | +8.7% |
| Apr 23, 2026 | +0.9% | Sold $2.9M | +3.2%S&P +0.4% | +1.9% |
| Feb 10, 2026 | -8.2% | None | +3.3%S&P -0.3% | +3.1% |
| Oct 30, 2025 | +12.7% | None | -0.3%S&P -0.8% | +5.1% |
| Jul 24, 2025 | +0.7% | None | +4.0%S&P +0.5% | +2.3% |
| Apr 23, 2025 | +2.3% | None | +6.4%S&P +3.7% | -0.2% |
| Feb 11, 2025 | +3.1% | None | +6.6%S&P -0.2% | -8.6% |
Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.
EW short selling
Daily short-sale volume as a share of trading volume (FINRA), with the 20-day average.
This is short volume from off-exchange trades, not short interest. It includes market makers' routine hedging, so 40–50% is normal; what stands out is a ratio well above the stock's own average. Insiders buying while shorts pile in →
Members of Congress who traded EW
From STOCK Act disclosures. Reported up to 45 days after the trade, in dollar ranges.
| Member | Trade | Traded | Reported | Since trade |
|---|---|---|---|---|
| Alan ArmstrongSenate | Bought $1,001 - $15,000 | Mar 27, 2026 | Jul 21, 2026 | +30.7% |
Insiders at Edwards Lifesciences
| Insider | Bought | Sold | Last filing | Past buys beat S&P | Score |
|---|---|---|---|---|---|
| Donald E. Bobo Jr.Cvp,Strategy/Corp Development | — | $16.2M | Nov 9, 2026 | — | — |
| Bernard J. ZovighianCEO | — | $9.4M | Nov 9, 2026 | — | — |
| Scott B. UllemCFO | — | $3.9M | May 11, 2026 | — | — |
| Daveen ChopraCvp, Tmtt, Surgical & Ihfm | — | $3.2M | Sep 11, 2026 | — | — |
| Wayne MarkowitzCvp, Japac | — | $1.0M | Sep 14, 2026 | — | — |
| Daniel J. LippisCvp, Tavr | — | $989K | Nov 10, 2026 | — | — |
| Annette BrulsCvp, Emeacla | — | $238K | Aug 28, 2026 | — | — |
| Heisz Leslie StoneDirector | — | $218K | May 8, 2026 | — | — |
| Andrew M. DahlSvp, Corporate Controller | — | $98K | Nov 13, 2026 | — | — |
| Theodora MistrasCFO | — | — | Jul 10, 2026 | — | — |
| Leslie C. DavisDirector | — | — | May 8, 2026 | — | — |
| David T. FeinbergDirector | — | — | May 8, 2026 | — | — |
| Kieran GallahueDirector | — | — | May 8, 2026 | — | — |
| Paul A. LavioletteDirector | — | — | May 8, 2026 | — | 100 |
| Steven R. LorangerDirector | — | — | May 8, 2026 | — | — |
| Ramona SequeiraDirector | — | — | May 8, 2026 | — | — |
| Nicholas J. ValerianiDirector | — | — | May 8, 2026 | — | — |
Board links: companies that share insiders with EW
Directors and executives who filed Form 4s for EW and another company in the last 12 months.
- HUMHumana David T. Feinberg Director here · Director at HUM · latest filing May 8, 2026
- ILMNIllumina Scott B. Ullem CFO here · Director at ILMN · latest filing Oct 2, 2026
- PLSEPulse Biosciences Paul A. Laviolette Director here · CEO at PLSE · latest filing May 11, 2026
- VTRSViatris Theodora Mistras CFO here · CFO at VTRS · latest filing Jul 10, 2026
Insider activity at other Health Care companies
Same sector, ranked by insider buying in the last 90 days.
EW stock: common questions
Are Edwards Lifesciences insiders buying EW stock?
No. No Edwards Lifesciences insider reported an open-market purchase of EW in the past 12 months.
Are Edwards Lifesciences insiders selling EW stock?
9 insiders reported sales worth $34.1M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is EW's P/E ratio?
EW trades at about 55.8 times trailing earnings, compared with a median of 25.0 for the Health Care sector.
What is EW's 52-week range?
Over the past year EW has traded between $75.87 and $107.15. It last closed at $103.72 on Nov 19, 2026.